Syntis Bio Raises $33M in Series A

Syntis Bio has successfully raised $33M in a Series A led by Cerberus Ventures.

Company Overview

Syntis Bio is a HealthTech company headquartered in Cambridge, MA, founded in 2022 with 50+ employees.

Developing oral therapies for obesity diabetes and rare diseases

Fundraising Details

• Amount Raised: $33M
• Round Type: Series A
• Date: 2025-06-14
• Investors: Cerberus Ventures

About Syntis Bio

Developing oral therapies for obesity diabetes and rare diseases The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: Cambridge, MA
• Founded: 2022
• Team Size: 50+
• Industry: HealthTech

What This Means

This funding round demonstrates strong investor confidence in Syntis Bio's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Syntis Bio's successful fundraising reflects the strong fundamentals and growth potential in this space.

Looking Ahead

With this new capital, Syntis Bio is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-06-14. For more information about Syntis Bio, visit their headquarters at Cambridge, MA.